Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6794141 | 0.99 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3708321 | 0.85 | MAOA (0.63) | KMT2AMEN1NPC1RAB9ACYP1A2 | |
| SCHEMBL7084144 | 0.83 | RAB9A (0.54) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL14005755 | 0.83 | MAPT (0.51) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6792301 | 0.83 | MEN1 (0.55) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6496190 | 0.82 | CYP1A2 (0.60) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6793640 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL31705591 | 0.80 | CYP1A2 (0.68) | ALDH1A1NPC1RAB9ACYP1A2MAPT | |
| SCHEMBL3826771 | 0.80 | CYP1A2 (0.68) | ALDH1A1NPC1RAB9ACYP1A2MAPT | |
| SCHEMBL6788102 | 0.79 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429278-B2 | N-alkyleheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'ORÉAL (FR) | 2008-09-30 | — | — | US | disclosed |
| US-7429278-B2 | N-alkyleheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'ORÉAL (FR) | 2008-09-30 | — | — | US | disclosed |
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | L'OREAL S.A. | 2008-03-20 | — | — | US | disclosed |
| US-20060005320-A1 | N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1589012-A2 | N-alkylheteroaryl secondary para-phenyldiamine, dyeing composition containing the same, process for making it and uses thereof | L'OREAL (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| CN-1478077-A | Benzamide compounds as APO B secretion inhibitors | ����ҩƷ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069789-A1 | N-ALKYLHETEROARYL SECONDARY PARA-PHENYLENEDIAMINE AND COMPOSITION COMPRISING SUCH A PARA-PHENYLENEDIAMINE | KRT18, CDC73, PRKDC | ALDH1A1 575/4885KMT2A 722/4885MEN1 2486/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | ALDH1A1 1427/4885KMT2A 2457/4885MEN1 2426/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | ALDH1A1 2174/4885KMT2A 916/4885MEN1 3820/4885 |
| US-20060005320-A1 | N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine | KRT18, CDC73, PRKDC | ALDH1A1 575/4885KMT2A 722/4885MEN1 2486/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ALDH1A1 1603/4885KMT2A 573/4885MEN1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.